[1] SUNG H, FERLAY J, SIEGEL R L et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality  Worldwide for 36 Cancers in 185 Countries.[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209–249. 

[2] BUZZONI R, BAJETTA E, DI BARTOLOMEO M et al. Pathological Features as Predictors of Recurrence after Radical Resection of Gastric  Cancer.[J]. The British Journal of Surgery, 2006, 93(2): 205–209. 

[3] SHITARA K, IWATA H, TAKAHASHI S et al. Trastuzumab Deruxtecan (DS-8201a) in Patients with Advanced HER2-Positive Gastric  Cancer: A Dose-Expansion, Phase 1 Study.[J]. The Lancet. Oncology, 2019, 20(6): 827–836. 

[4] PENG Z, LIU T, WEI J et al. Efficacy and Safety of a Novel Anti-HER2 Therapeutic Antibody RC48 in Patients with  HER2-Overexpressing, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer: A Single-Arm Phase II Study.[J]. Cancer Communications (London, England), 2021, 41(11): 1173–1182. 

[5] JANJIGIAN Y Y, KAWAZOE A, YAÑEZ P et al. The KEYNOTE-811 Trial of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric  Cancer.[J]. Nature, 2021, 600(7890): 727–730. DOI:10.1038/s41586-021-04161-3.

[6] YELENA Y. JANJIGIAN AK, PATRICIO EDUARDO YANEZ  et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study[J]. J Clin Oncol, 2021, suppl 15(39).

[7] J GONG LS, S LUO  et al. Preliminary efficacy and safety results of KN026 (a HER2- targeted bispecific antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in patients (pts) with HER2-positive gastrointestinal tumors[J]. Annals of Oncology, 2021, 32(suppl_5): S1040–S1075.

[8] D.V. CATENACCI HP, B.Y. SHIM  et al. Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A[J]. Annals of Oncology, 2021, 32(suppl_5): S1040–S1075.

[9] C. QI YQ, D. LIU  et al. CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system[J]. Annals of Oncology, 2021, 32(suppl_5): S1040–S1075.

[10] XU R-H, ZHANG Y, PAN H et al. Efficacy and Safety of Weekly Paclitaxel with or without Ramucirumab as Second-Line  Therapy for the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (RAINBOW-Asia): A Randomised, Multicentre, Double-Blind, Phase 3 Trial.[J]. The Lancet. Gastroenterology & Hepatology, 2021, 6(12): 1015–1024. 

[11] JANJIGIAN Y Y, SHITARA K, MOEHLER M et al. First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced  Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial.[J]. Lancet (London, England), 2021, 398(10294): 27–40. 

[12] J. XU HJ, Y. PAN  et al. Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study[J]. Annals of Oncology, 2021, 32(suppl_5): S1283–S1346.

[13] BATLLE E, MASSAGUÉ J. Transforming Growth Factor-β Signaling in Immunity and Cancer.[J]. Immunity, 2019, 50(4): 924–940. 

[14] BAXTER M A, MIDDLETON F, CAGNEY H P et al. Resistance to Immune Checkpoint Inhibitors in Advanced Gastro-Oesophageal Cancers.[J]. British Journal of Cancer, 2021, 125(8): 1068–1079. 

[15] FUKUOKA S, HARA H, TAKAHASHI N et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer:  An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).[J]. Journal of Clinical Oncology : Official Journal of the American Society of Clinical  Oncology, 2020, 38(18): 2053–2061. 

[16] KAWAZOE A, FUKUOKA S, NAKAMURA Y et al. Lenvatinib plus Pembrolizumab in Patients with Advanced Gastric Cancer in the  First-Line or Second-Line Setting (EPOC1706): An Open-Label, Single-Arm, Phase 2 Trial.[J]. The Lancet. Oncology, 2020, 21(8): 1057–1065. 

[17] AL C H et. LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort[J]. Journal of Clinical Oncology, 2021, 39((15_suppl)): 4030–4030.

[18] HERBST R S, ARKENAU H-T, SANTANA-DAVILA R et al. Ramucirumab plus Pembrolizumab in Patients with Previously Treated Advanced  Non-Small-Cell Lung Cancer, Gastro-Oesophageal Cancer, or Urothelial Carcinomas (JVDF): A Multicohort, Non-Randomised, Open-Label, Phase 1a/b Trial.[J]. The Lancet. Oncology, 2019, 20(8): 1109–1123. 

[19] NAKAJIMA T E, KADOWAKI S, MINASHI K et al. Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab  as Second-Line Treatment in Patients with Advanced Gastric Cancer.[J]. Clinical Cancer Research : An Official Journal of the American Association for  Cancer Research, 2021, 27(4): 1029–1036. 

[20] AL T Z et. 1385P Phase II study of neoadjuvant camrelizumab combined with chemoradiation for locally advanced proximal gastric cancer (Neo-PLANET, NCT03631615)[J]. Annals of Oncology, 2021, 32: S1049.

[21] AL T S et. Neoadjuvant nivolumab monotherapy in patients with resectable gastric cancer: Preliminary results from a multicenter study[J]. Journal of Clinical Oncology, 2021, 39((15_suppl)): 4026–4026.

[22] HYUNG W J, YANG H-K, PARK Y-K et al. Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric  Cancer: The KLASS-02-RCT Randomized Clinical Trial.[J]. Journal of Clinical Oncology : Official Journal of the American Society of Clinical  Oncology, 2020, 38(28): 3304–3313. 

[23] LU J, ZHENG C-H, XU B-B et al. Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer: A  Randomized Controlled Trial.[J]. Annals of Surgery, 2021, 273(5): 858–867.

[24] CHEN Q-Y, XIE J-W, ZHONG Q et al. Safety and Efficacy of Indocyanine Green Tracer-Guided Lymph Node Dissection During  Laparoscopic Radical Gastrectomy in Patients With Gastric Cancer: A Randomized Clinical Trial.[J]. JAMA Surgery, 2020, 155(4): 300–311. 

[25] SMALLEY S R, BENEDETTI J K, HALLER D G et al. Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of  Adjuvant Radiochemotherapy versus Observation after Curative Gastric Cancer Resection.[J]. Journal of Clinical Oncology : Official Journal of the American Society of Clinical  Oncology, 2012, 30(19): 2327–2333. 

[26] PARK S H, LIM D H, SOHN T S et al. A Randomized Phase III Trial Comparing Adjuvant Single-Agent S1, S-1 with  Oxaliplatin, and Postoperative Chemoradiation with S-1 and Oxaliplatin in Patients with Node-Positive Gastric Cancer after D2 Resection: The ARTIST 2 Trial.[J]. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2021, 32(3): 368–374. 

[27] LEE J, LIM D H, KIM S et al. Phase III Trial Comparing Capecitabine plus Cisplatin versus Capecitabine plus  Cisplatin with Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer with D2 Lymph Node Dissection: The ARTIST Trial.[J]. Journal of Clinical Oncology : Official Journal of the American Society of Clinical  Oncology, 2012, 30(3): 268–273. 

[28] ZHOU M-L, YANG W, WANG Y-Q et al. Adjuvant Chemoradiotherapy versus Adjuvant Chemotherapy for Patients with N3 Gastric  Cancer after D2/R0 Resection: A Retrospective Study Based on Propensity Score Analyses.[J]. Cancer Management and Research, 2019, 11: 4855–4870. 

[29] VAN DER WOUDE S O, HULSHOF M C C M, VAN LAARHOVEN H W M. CROSS and beyond: A Clinical Perspective on the Results of the Randomized  ChemoRadiotherapy for Oesophageal Cancer Followed by Surgery Study.[J]. Chinese Clinical Oncology, 2016, 5(1): 13. 

[30] STAHL M, WALZ M K, RIERA-KNORRENSCHILD J等. Preoperative Chemotherapy versus Chemoradiotherapy in Locally Advanced  Adenocarcinomas of the Oesophagogastric Junction (POET): Long-Term Results of a Controlled Randomised Trial.[J]. European Journal of Cancer (Oxford, England : 1990), 2017, 81: 183–190. 

[31] LEONG T, SMITHERS B M, HAUSTERMANS K et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or  Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.[J]. Annals of Surgical Oncology, 2017, 24(8): 2252–2258.